Vaccine Therapy for Patients With Stage III Melanoma

Phase 3

• Conditions: Malignant Melanoma

• Registration Number: NCT00052130
• Lead Sponsor: CancerVax Corporation

Brief Summary

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-01-22
• Study First Submitted QC: 2003-01-23
• Study First Posted: 2003-01-24
• Status Verified: 2004-09
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1118

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (78)

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

Central Arkansas Veterans Healthcare System; 🇺🇸 Little Rock, Arkansas, United States

University of Arkansas for Medical Sciences; 🇺🇸 Little Rock, Arkansas, United States

Kaiser Permanente Medical Group; 🇺🇸 San Diego, California, United States

Cedars Sinai Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Hoag Memorial Hospital Presbyterian; 🇺🇸 Newport Beach, California, United States

Comprehensive Cancer Center at DRMC; 🇺🇸 Palm Springs, California, United States

Sharp Hospital; 🇺🇸 San Diego, California, United States

UCSF Cancer Center and Cancer Research Institute; 🇺🇸 San Francisco, California, United States

University of Colorado Cancer Center; 🇺🇸 Aurora, Colorado, United States

Scroll for more (68 remaining)